Protalix Biotherapeutics Inc

Price Chart

Risk-Adjusted Performance

Protalix Biotherapeutics Inc (PLX) Price Performance

Protalix Biotherapeutics Inc (PLX) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $2.07, down 3.27% from the previous close.

Over the past year, PLX has traded between a low of $1.35 and a high of $3.15. The stock has lost 16.5% over this period. It is currently 34.3% below its 52-week high.

Protalix Biotherapeutics Inc has a market capitalization of $171.62M, with a price-to-earnings ratio of 58.53.

About Protalix Biotherapeutics Inc

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.